<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-056150</identifier>
<setSpec>1137-2273</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Subdermal hormonal implant: an experience in a clinical unit</dc:title>
<dc:description xml:lang="en">In Spain, the number of Volutary Interruptions of Pregnancy is high, as well as the rate of unintended pregnancies. Recently, the range of contraceptive methods available for Spaniards has widened considerably. Some of them, which were already available in other countries, have been introduced in Spain, such as the Subcutaneous Hormoonal Implant, regarded as the most effective contraceptive nowadays. Furthermore, it shows a great risk/benefit balance. The aim of this paper is the analysis of the users profile, the adverse effects, the degree of satisfaction and the methos used for women to carry the subdermal hormonal implant</dc:description>
<dc:creator>Ábalos Medina, G. M</dc:creator>
<dc:creator>Martínez Cañavate, T</dc:creator>
<dc:creator>Jiménez Alonso, E</dc:creator>
<dc:creator>Ruiz Villaverde, G</dc:creator>
<dc:creator>Rivas del Valle, P</dc:creator>
<dc:creator>Montero López, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En España el número de Interrupciones Voluntarias de Embarazo (IVE) es elevado, así como la tasa de embarazos no deseados. en los últimos años ha variado notablemente el abanico de métodos anticonceptivos disponibles en nuestro país. Algunos de ellos, ya disponibles en otros países, se han introducido aquí, como es el caso del implante hormonal subcutáneo (IHS), considerado en la actualidad el anticonceptivo más eficaz, presentando además un excelente balance riesgo/beneficio. En el presente trabajo se analiza el perfil de las usuarias, así como los efectos adversos, grado de satisfacción e indicación del implante hormonal subcutáneo (IHS)</dc:description>
<dc:source>Cienc. ginecol;11(2): 108-111, mar.-abr. 2007. ilus</dc:source>
<dc:identifier>ibc-056150</dc:identifier>
<dc:title xml:lang="es">Implante hormonal subcutáneo: experiencia en una unidad clínica</dc:title>
<dc:subject>^d331</dc:subject>
<dc:subject>^d3290^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d4405</dc:subject>
<dc:subject>^d38342^s22083</dc:subject>
<dc:subject>^d13411^s22080</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d29902^s22083</dc:subject>
<dc:subject>^d32048^s22083</dc:subject>
<dc:subject>^d11709^s22083</dc:subject>
<dc:type>article</dc:type>
<dc:date>200704</dc:date>
</metadata>
</record>
</ibecs-document>
